Erratum: Disseminated aspergillosis following resolution of pneumocystis pneumonia with sustained elevation of beta-glucan in an intensive care unit: A case report (Infection (2009) 37 (547-550) DOI: 10.1007/s15010-009-8108-5);Disseminated aspergillosis following resolution of pneumocystis pneumonia with sustained elevation of beta-glucan in an intensive care unit: A case report

Infection

Volumn 37, Issue 6, 2009, Pages 547-550

  Saito, T ^a   Shime, N ^b   Itoh, K ^c   Fujita, N ^b   Saito, Y ^a   Shinozaki, M ^d   Shibuya, K ^d   Makimura, K ^e   Hashimoto, S ^b  

^a KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PROTEINASE; BETA GLUCAN; COTRIMOXAZOLE; FOSFLUCONAZOLE; GALACTOMANNAN; GLOMERULUS BASEMENT MEMBRANE ANTIBODY; IMMUNOGLOBULIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

ACUTE RESPIRATORY FAILURE; ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; AUTOPSY; BLOOD CULTURE; CASE REPORT; CAUSE OF DEATH; ENDOTRACHEAL INTUBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOODPASTURE SYNDROME; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; IN SITU HYBRIDIZATION; INTENSIVE CARE UNIT; MULTIPLE ORGAN FAILURE; MYCOSIS; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION;

EID: 77249125399     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-010-3108-z     Document Type: Erratum

References (20)

1. Denning DW: Invasive aspergillosis. Clin Infect Dis 1998; 26:781-805.
2. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate:systemic review of the literature. Clin Infect Dis 2001; 32:358-366.
3. Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M:Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999;37: 1732-1738.
4. Dasbach EJ, Davis GM, Teusch SM: Burden of aspergillosisrelated hospitalization in the United States. Clin Infect Dis 2000; 31: 1524-1528.
5. Thomas CM, Neil SY: The relationship of pre mortem diagnosis and post mortem findings in a surgical intensive care unit. Crit Care Med 1999; 27: 299-303.
6. Ascioglu S, Rex JH, de Pauw BE, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infection in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
7. de Pauw BE, Patterson TF: Should the consensus guidelines' specific criteria for diagnosis of invasive fungal infection be changed? Clin Infect Dis 2005; 41: S377-S380.
8. Maertens J, Theunissen K, Verbeken E, Lagrou K, Verhaegen J, et al. Prospective clinical evaluation of lower cut-offs for galactomannan detection in adult neutropenic cancer patients and haematological stem cell transplant recipients. Br J Haematol 2004; 126: 852-860.
9. Hanazawa R, Yamagata S, Yamaguchi H: In situ detection of Aspergillus fumuigatus. J Med Microbiol 2000; 49: 285-290.
10. Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD: Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int 2004; 66: 1535-1540.
11. Mennink-Kersten MA, Donnelly JP, Verweij PE: Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004; 4: 349-357.
12. Pfeiffer CD, Fine JP, Safdar N: Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417-1427.
13. Aquino VR, Goldani LZ, Pasqualotto AC: Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia 2007; 163: 191-202.
14. Francis P, Lee JW, Hoffman A, Peter J, Francesconi A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of br onchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994; 169: 356-368.
15. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, et al. b-D-Glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39: 199-205.
16. Pazos C, Ponto J, Del Palacio A: Contribution of (1 fi 3)- b-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol 2005; 43: 299-305.
17. Tasaka S, Hasegawa N, Kobayashi S, Yamada W, Nishimura T, et al. Serum indicators for the diagnosis of Pneumocystis pneumonia. Chest 2007; 131: 1173-1180.
18. Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A: Elevation of blood (1 fi 3)-beta-D-glucan concentrations in hemodialysis patients. Nephron 2001; 89: 15-19.
19. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
20. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.